Hospital-Treated Gram-Negative Infections Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Size, Share & Trends, Drivers, Restraints, Opportunities, Manufacturer, Applications, And Segments

  • AMR-1063695
  • May 2021
  • Pharmaceuticals
  • 115 Pages
The Hospital-Treated Gram-Negative Infections Market research report comprises of an overall in depth-analysis such as market drivers, opportunities, restraints, latest developments and trends, segmentation of the market, competitive analysis, global as well as regional analysis by showcasing how each of these factors can improve the further growth of the market on an overall perspective. The report also showcases the overall market value which includes the historic data (2018-2019) and forecast data (2020-2028) generated through the revenue (USD Mn)
 
Report Parameters Details of Parameter
Market Size xx Million
Based Year 2020
Forecast Period Covered 2020 – 2028
Units for value Revenue in USD million and CAGR from 2020 to 2028
Covered Segments Component, Types, Applications, End-Users, and more.
Companies Covered Merck and Co., Inc., Pfizer Inc., AstraZeneca plc, Abbott Laboratories, Lupin Limited, Istituto Lusofarmaco D\'Italia SpA, ADELCO, Zhejiang yuntao biotechnology co., Ltd, GlaxoSmithKline plc, Novartis International AG
Region Covered North America, Europe, Asia Pacific, Latin America, Middle East and Africa

COVID-19 Coverage
With the beginning of the COVID-19 pandemic in early 2020, all major economies around the world enforced severe lockdown restrictions to curb the spread of the virus. Apart from a few sectors such as healthcare and related essential services, most of the industries suffered tremendously due to inability to function in a normal fashion. Moreover, even some of the essential sectors suffered due to delays caused by supply chain disruptions and other travel complexities. However, with massive vaccination drives in most of the developed economies, some of the economies across the world experienced economic recovery from 2021. The Hospital-Treated Gram-Negative Infections market is expected to gain momentum in such economies and probably recover some of the losses inflicted in the year 2020. With continued efforts towards curbing the virus in the developing economies, the Hospital-Treated Gram-Negative Infections market is expected to attain Pre COVID-19 levels by mid-2022.

Hospital-Treated Gram-Negative Infections Report’s Assessment
The research report is formulated such that it offers a deep understating on the market drivers that are assimilating the growth of the market, the market opportunities that are going to provide future growth factors for the market and the market restraints which showcase the reasons as to why the market can get hampered and dissimilated. All these factors are considered keeping in view the historic and forecast analysis which can enlighten the above mentioned factors.

Thereby at a glance a reader can understand all the factors and prospects of the Hospital-Treated Gram-Negative Infections market and how it can assimilate and dissimilate based on each of the factors and figures mentioned in the report

Hospital-Treated Gram-Negative Infections Market Competitive and Premeditated Analysis
In the Hospital-Treated Gram-Negative Infections report major factors such latest tactical developments, competitors, research and development, participation of each region in the market and the competition among them, the latest news regarding company acquisitions and product launch, revenue of the competitors as well as the key offerings they provide all these factors are mentioned in the report with reasons to justify and understand them in depth.

The readers and purchaser of the Hospital-Treated Gram-Negative Infections research report can gain a comprehensive understanding of the market competition, the revenue of each major players and their contribution towards the market, attractive proposition analysis is provided in the report which sub divides the segments with respect to the largest segment that has contributed to the market growth and the fastest growing segment based on the size of the market as well as its overall appeal.
 
Major Key Players for Global Hospital-Treated Gram-Negative Infections Market:
The Hospital-Treated Gram-Negative Infections market research report offers the company profile of major key players including progress trends, competitive landscape breakdown, and key in regions development status. Merck and Co., Inc., Pfizer Inc., AstraZeneca plc, Abbott Laboratories, Lupin Limited, Istituto Lusofarmaco D\'Italia SpA, ADELCO, Zhejiang yuntao biotechnology co., Ltd, GlaxoSmithKline plc, Novartis International AG

The Hospital-Treated Gram-Negative Infections market report showcases vast potentials of growth and assimilation which is going to provide the industry numerous opportunities to grow and generate revenue by understanding the segments and which segment is a potential part to increase the disposable income in the present and upcoming years.

Hospital-Treated Gram-Negative Infections Market Segmentation Analysis:
Each of the segment is explained in brief along with the revenue it generates for the market based on the historic and forecast data by highlighting the largest segment and the fastest growing segment with reasons to justify it.

The Global segmentation of the Hospital-Treated Gram-Negative Infections market:
By Type
Klebsiella
Acinetobacter
Coli
Cepacia
Pseudomonas
Serratia
Enterobacter
Others
End User
Hospital
Lab

Regional Analysis of the Hospital-Treated Gram-Negative Infections market:
The Hospital-Treated Gram-Negative Infections market is dived based on different regions such as North America, Europe, Asia Pacific, Latin America and the Middle East and Africa. And the analysis of each region is provided by highlighting the largest contribution region, the fastest growing region and the factors that is keeping the market active in the other regions is also mentioned in depth. Each regional segment also comprises of the revenue each segment holds in a specific region with reasons to justify the values.

By Regions:
  • North America (U.S and Canada)
  • Europe (U.K., Germany and France)
  • Asia Pacific (China, India and Japan)
  • Latin America (Mexico and Brazil)
  • Middle East and Africa (GCC Countries and South Africa)
 


Major Factors Included and highlighted in the Hospital-Treated Gram-Negative Infections report are as follows:
  • The overall market value along with historic and future data analysis.
  • The Growth drivers, opportunities and restraints are mention in detail.
  • The size of the entire Hospital-Treated Gram-Negative Infections market on a global perspective.
  • The CAGR value of the overall market from 2020 to 2028.
  • COVID-19 impact on the Hospital-Treated Gram-Negative Infections market and how it is coping up with the situation.
  • Major competitors and their contribution towards the market.
  • The segmentation analysis is included which provides a clear picture of the market bifurcation.
  • Tables and graphs that can easily been understood at a glance
  • Latest trends and news related to the Hospital-Treated Gram-Negative Infections market is included in the report.
Key Analytical Areas:
The report aims to offer a complete solution to various businesses operating in the Hospital-Treated Gram-Negative Infections market in making strategic decisions based on credible information and actionable insights. Thereby, the report covers various aspects of your requirements such as industry overview, market dynamics, regional analysis and competitive landscape. The report aims to provide insights to businesses in the Hospital-Treated Gram-Negative Infections market for numerous purposes such as:

     1. Strategic Decision Making:
With the help of this report, key decision makers can quickly analyze and identify growth opportunities in terms of numerous segments across various geographical regions. Thereby, this report enables organizations to identify and make strategic investments in specific market segments in order to gain maximum return on investment.

     2. Actionable Insights:
The report offers a deep dive into how companies are leveraging market conditions to make the most in the Hospital-Treated Gram-Negative Infections market. Thereby, the report offers numerous actionable insights into the best practices and key success factors relevant in the Hospital-Treated Gram-Negative Infections market. Using the insights included in the report, businesses can make quick decisions to achieve success in business operations.

     3. Competitive Snapshot:
In addition, to detailed information on the companies operating in the Hospital-Treated Gram-Negative Infections market, the report also includes a competitive snapshot of all the companies covered in the report. Thereby, this offers a visual representation of how all the companies stand comparatively based on their competencies, geographic presence, market hold, years of operations, employee and financial strength, among others.

Manufacturers and Segments

  • Merck and Co., Inc.
  • Pfizer Inc.
  • AstraZeneca plc
  • Abbott Laboratories
  • Lupin Limited
  • Istituto Lusofarmaco D'Italia SpA
  • ADELCO
  • Zhejiang yuntao biotechnology co., Ltd
  • GlaxoSmithKline plc
  • Novartis International AG
  • Klebsiella
  • Acinetobacter
  • Coli
  • Cepacia
  • Pseudomonas
  • Serratia
  • Enterobacter
  • Others
  • Hospital
  • Lab

Have query on this report?

Make an Enquiry
1. Preface
     1.1. Report Scope and Description
     1.2. Research Methodology
          1.2.1. Phase I-Secondary Research
          1.2.2. Phase II-Primary Research
          1.2.3. Phase II-Expert Panel Review
          1.2.4. Assumptions
          1.2.5. Approach Adopted

2. Executive Summarysegment Form
     2.1. Global Hospital-Treated Gram-Negative Infections Market Snapshot
          2.1.1. Global Hospital-Treated Gram-Negative Infections Market By Type,2019
               2.1.1.1.Klebsiella
               2.1.1.2.Acinetobacter
               2.1.1.3.Coli
               2.1.1.4.Cepacia
               2.1.1.5.Pseudomonas
               2.1.1.6.Serratia
               2.1.1.7.Enterobacter
               2.1.1.8.Others
          2.1.2. Global Hospital-Treated Gram-Negative Infections Market By End User,2019
               2.1.2.1.Hospital
               2.1.2.2.Lab
          2.1.3. Global Hospital-Treated Gram-Negative Infections Market By End-use,2019
          2.1.4. Global Hospital-Treated Gram-Negative Infections Market By Geography,2019

3. Global Hospital-Treated Gram-Negative Infections Market Dynamics
     3.1. Market Overview
     3.2. Market Inclination Insights Analysis
     3.3. Drivers
     3.4. Challenges
     3.5. Future Prospects
     3.6. Impact Analysis of Drivers and Challenges During the Forecast Period, (2020-2028)

4. Global Hospital-Treated Gram-Negative Infections Market Size (US$), By Type, 2018 – 2028 
     4.1. Overview
          4.1.1. Market Share Analysis By Type, 2019 vs.2028
          4.1.2. Attractive Investment Proposition By Type, 2020
     4.2. Global Hospital-Treated Gram-Negative Infections Market Size (US$), By Type, 2018 – 2028

5. Global Hospital-Treated Gram-Negative Infections Market Size (US$), By End User, 2018 – 2028 
     5.1. Overview
          5.1.1. Market Share Analysis By End User, 2019 vs.2028
          5.1.2. Attractive Investment Proposition By End User, 2020
     5.2. Global Hospital-Treated Gram-Negative Infections Market Size (US$), By End User, 2018 – 2028

6. Global Hospital-Treated Gram-Negative Infections Market Size (US$), By End-use, 2018 – 2028 
     6.1. Overview
          6.1.1. Market Share Analysis By End-use, 2019 vs.2028
          6.1.2. Attractive Investment Proposition By End-use, 2020
     6.2. Global Hospital-Treated Gram-Negative Infections Market Size (US$), By End-use, 2018 – 2028

7. Global Hospital-Treated Gram-Negative Infections Market Size (US$), By Geography, 2018 – 2028
     7.1. Overview
          7.1.1. Market Share Analysis by Geography, 2019 vs. 2028
          7.1.2. Attractive Investment Proposition by Geography, 2020
     7.2. North America Hospital-Treated Gram-Negative Infections Market Analysis, 2018 – 2028 
          7.2.1. North America Hospital-Treated Gram-Negative Infections Market Size (US$), By Country, 2018 – 2028 
               7.2.1.1. U.S.
               7.2.1.2. Canada
          7.2.2. North America Hospital-Treated Gram-Negative Infections Market Size (US$), By Type, 2018 – 2028
          7.2.3. North America Hospital-Treated Gram-Negative Infections Market Size (US$), By End User, 2018 – 2028
          7.2.4. North America Hospital-Treated Gram-Negative Infections Market Size (US$), By End-use, 2018 – 2028
     7.3. Europe Hospital-Treated Gram-Negative Infections Market Analysis, 2018 – 2028 
          7.3.1.  Europe Hospital-Treated Gram-Negative Infections Market Size (US$), By Country, 2018 – 2028 
               7.3.1.1. U.K.
               7.3.1.2. Germany
               7.3.1.3. France
               7.3.1.4. Rest of Europe
          7.3.2. Europe Hospital-Treated Gram-Negative Infections Market Size (US$), By Type, 2018 – 2028
          7.3.3. Europe Hospital-Treated Gram-Negative Infections Market Size (US$), By End User, 2018 – 2028
          7.3.4. Europe Hospital-Treated Gram-Negative Infections Market Size (US$), By End-use, 2018 – 2028
     7.4. Asia Pacific Hospital-Treated Gram-Negative Infections Market Analysis , 2018 – 2028
          7.4.1.  Asia Pacific Hospital-Treated Gram-Negative Infections Market Size (US$), By Country, 2018 – 2028 
               7.4.1.1. China
               7.4.1.2. Japan
               7.4.1.3. India
               7.4.1.4. Rest of Asia Pacific
          7.4.2. Asia Pacific Hospital-Treated Gram-Negative Infections Market Size (US$), By Type, 2018 – 2028
          7.4.3. Asia Pacific Hospital-Treated Gram-Negative Infections Market Size (US$), By End User, 2018 – 2028
          7.4.4. Asia Pacific Hospital-Treated Gram-Negative Infections Market Size (US$), By End-use, 2018 – 2028
     7.5. Latin America Hospital-Treated Gram-Negative Infections Market Analysis, 2018 – 2028 
          7.5.1.  Latin America Hospital-Treated Gram-Negative Infections Market Size (US$), By Country, 2018 – 2028 
               7.5.1.1. Brazil
               7.5.1.2. Mexico
               7.5.1.3. Rest of Latin America
          7.5.2. Latin America Hospital-Treated Gram-Negative Infections Market Size (US$), By Type, 2018 – 2028
          7.5.3. Latin America Hospital-Treated Gram-Negative Infections Market Size (US$), By End User, 2018 – 2028
          7.5.4. Latin America Hospital-Treated Gram-Negative Infections Market Size (US$), By End-use, 2018 – 2028
     7.6. Middle East & Africa (MEA) Hospital-Treated Gram-Negative Infections Market Analysis, 2018 – 2028 
          7.6.1.  MEA Hospital-Treated Gram-Negative Infections Market Size (US$), By Region, 2018 – 2028 
               7.6.1.1. GCC Countries
               7.6.1.2. South Africa
               7.6.1.3. Rest of MEA
          7.6.2. MEA Hospital-Treated Gram-Negative Infections Market Size (US$), By Type, 2018 – 2028
          7.6.3. MEA Hospital-Treated Gram-Negative Infections Market Size (US$), By End User, 2018 – 2028
          7.6.4. MEA Hospital-Treated Gram-Negative Infections Market Size (US$), By End-use, 2018 – 2028

8. Company Profiles
     8.1. Competitive Analysis 
     8.2. Market Positioning of Key Vendors 
     8.3. Key Strategies adopted by the Leading Players
     8.4. Key Hospital-Treated Gram-Negative Infections Providers
        8.4.1 Merck and Co., Inc.
                8.4.1.1 Business Description
                8.4.1.2 Merck and Co., Inc. Geographic Operations
                8.4.1.3 Merck and Co., Inc. Financial Information
                8.4.1.4 Merck and Co., Inc. Product Positions/Portfolio
                8.4.1.5 Merck and Co., Inc. Key Developments
        8.4.2 Pfizer Inc.
                8.4.2.1 Business Description
                8.4.2.2 Pfizer Inc. Geographic Operations
                8.4.2.3 Pfizer Inc. Financial Information
                8.4.2.4 Pfizer Inc. Product Positions/Portfolio
                8.4.2.5 Pfizer Inc. Key Developments
        8.4.3 AstraZeneca plc
                8.4.3.1 Business Description
                8.4.3.2 AstraZeneca plc Geographic Operations
                8.4.3.3 AstraZeneca plc Financial Information
                8.4.3.4 AstraZeneca plc Product Positions/Portfolio
                8.4.3.5 AstraZeneca plc Key Developments
        8.4.4 Abbott Laboratories
                8.4.4.1 Business Description
                8.4.4.2 Abbott Laboratories Geographic Operations
                8.4.4.3 Abbott Laboratories Financial Information
                8.4.4.4 Abbott Laboratories Product Positions/Portfolio
                8.4.4.5 Abbott Laboratories Key Developments
        8.4.5 Lupin Limited
                8.4.5.1 Business Description
                8.4.5.2 Lupin Limited Geographic Operations
                8.4.5.3 Lupin Limited Financial Information
                8.4.5.4 Lupin Limited Product Positions/Portfolio
                8.4.5.5 Lupin Limited Key Developments
        8.4.6 Istituto Lusofarmaco D'Italia SpA
                8.4.6.1 Business Description
                8.4.6.2 Istituto Lusofarmaco D'Italia SpA Geographic Operations
                8.4.6.3 Istituto Lusofarmaco D'Italia SpA Financial Information
                8.4.6.4 Istituto Lusofarmaco D'Italia SpA Product Positions/Portfolio
                8.4.6.5 Istituto Lusofarmaco D'Italia SpA Key Developments
        8.4.7 ADELCO
                8.4.7.1 Business Description
                8.4.7.2 ADELCO Geographic Operations
                8.4.7.3 ADELCO Financial Information
                8.4.7.4 ADELCO Product Positions/Portfolio
                8.4.7.5 ADELCO Key Developments
        8.4.8 Zhejiang yuntao biotechnology co., Ltd
                8.4.8.1 Business Description
                8.4.8.2 Zhejiang yuntao biotechnology co., Ltd Geographic Operations
                8.4.8.3 Zhejiang yuntao biotechnology co., Ltd Financial Information
                8.4.8.4 Zhejiang yuntao biotechnology co., Ltd Product Positions/Portfolio
                8.4.8.5 Zhejiang yuntao biotechnology co., Ltd Key Developments
        8.4.9 GlaxoSmithKline plc
                8.4.9.1 Business Description
                8.4.9.2 GlaxoSmithKline plc Geographic Operations
                8.4.9.3 GlaxoSmithKline plc Financial Information
                8.4.9.4 GlaxoSmithKline plc Product Positions/Portfolio
                8.4.9.5 GlaxoSmithKline plc Key Developments
        8.4.10 Novartis International AG
                8.4.10.1 Business Description
                8.4.10.2 Novartis International AG Geographic Operations
                8.4.10.3 Novartis International AG Financial Information
                8.4.10.4 Novartis International AG Product Positions/Portfolio
                8.4.10.5 Novartis International AG Key Developments

LIST OF TABLES

TABLE 1 Market Snapshot: Global Hospital-Treated Gram-Negative Infections Market 
TABLE 2 Impact Indicators 
TABLE 3 Impact Analysis of Drivers and Restraints 
TABLE 4 North America Hospital-Treated Gram-Negative Infections Market Revenue, By Type, 2018 – 2028 (US$ Mn) 
TABLE 5 North America Hospital-Treated Gram-Negative Infections Market Revenue, By End User, 2018 – 2028 (US$ Mn) 
TABLE 6 North America Hospital-Treated Gram-Negative Infections Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 7 Europe Hospital-Treated Gram-Negative Infections Market Revenue, By Type, 2018 – 2028 (US$ Mn) 
TABLE 8 Europe Hospital-Treated Gram-Negative Infections Market Revenue, By End User, 2018 – 2028 (US$ Mn) 
TABLE 9 Europe Hospital-Treated Gram-Negative Infections Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 10 Asia Pacific Hospital-Treated Gram-Negative Infections Market Revenue, By Type, 2018 – 2028 (US$ Mn) 
TABLE 11 Asia Pacific Hospital-Treated Gram-Negative Infections Market Revenue, By End User, 2018 – 2028 (US$ Mn) 
TABLE 12 Asia Pacific Hospital-Treated Gram-Negative Infections Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 13 Latin America Hospital-Treated Gram-Negative Infections Market Revenue, By Type, 2018 – 2028 (US$ Mn) 
TABLE 14 Latin America Hospital-Treated Gram-Negative Infections Market Revenue, By End User, 2018 – 2028 (US$ Mn) 
TABLE 15 Latin America Hospital-Treated Gram-Negative Infections Market Revenue, By End-use, 2018 – 2028 (US$ Mn)
TABLE 16 MEA Hospital-Treated Gram-Negative Infections Market Revenue, By Type, 2018 – 2028 (US$ Mn) 
TABLE 17 MEA Hospital-Treated Gram-Negative Infections Market Revenue, By End User, 2018 – 2028 (US$ Mn) 
TABLE 18 MEA Hospital-Treated Gram-Negative Infections Market Revenue, By End-use, 2018 – 2028 (US$ Mn)

LIST OF FIGURES

FIG. 1 Global Hospital-Treated Gram-Negative Infections: Market Segmentation 
FIG. 2 Global Hospital-Treated Gram-Negative Infections Market: Research Methodology 
FIG. 3 Top-Down and Bottom-up Approach 
FIG. 4 Global Hospital-Treated Gram-Negative Infections Market, By Type, 2019 (US$ Mn) 
FIG. 5 Global Hospital-Treated Gram-Negative Infections Market, By End User, 2019 (US$ Mn) 
FIG. 6 Global Hospital-Treated Gram-Negative Infections Market, By End-use, 2019 (US$ Mn) 
FIG. 7 Global Hospital-Treated Gram-Negative Infections Market, By Geography, 2019 (US$ Mn) 
FIG. 8 Global Hospital-Treated Gram-Negative Infections Market Revenue and Growth, 2018 – 2028, (US$ Mn) (Y-o-Y %)
FIG. 9 Attractive Investment Proposition 
FIG. 10 Market Positioning of Key Hospital-Treated Gram-Negative Infections Providers, 2019
FIG. 11 Global Hospital-Treated Gram-Negative Infections Market Revenue Contribution, By Type, 2019 & 2028 (Value %) 
FIG. 12 Global Hospital-Treated Gram-Negative Infections Market Revenue Contribution, By End User, 2019 & 2028 (Value %) 
FIG. 13 Global Hospital-Treated Gram-Negative Infections Market Revenue Contribution, By End-use, 2019 & 2028 (Value %) 
FIG. 14 North America Hospital-Treated Gram-Negative Infections Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 15 Europe Hospital-Treated Gram-Negative Infections Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 16 Asia Pacific Hospital-Treated Gram-Negative Infections Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 17 Latin America Hospital-Treated Gram-Negative Infections Market Revenue, 2018 – 2028, (US$ Mn)
FIG. 18 MEA Hospital-Treated Gram-Negative Infections Market Revenue, 2018 – 2028, (US$ Mn)

Key Takeaways:

1. Market value and estimate of the Hospital-Treated Gram-Negative Infections market for the period from 2020 to 2028
2. Compounded annual growth rate (CAGR%) for individual segments in various regional markets for a period from 2020 to 2028
3. Value chain analysis
4. Market share study combined with competitive landscape of major players
5. Profiles of major market players covering overall business operations, geographic occurrence, product portfolio, financial status and news coverage 

List of Tables

TABLE  Market Snapshot: Global Hospital-Treated Gram-Negative Infections Market
TABLE  Impact Pointers
TABLE  Impact Analysis of Drivers and Restraints
TABLE  North America Hospital-Treated Gram-Negative Infections Market Value, By Segment1, 2018 – 2028
TABLE  North America Hospital-Treated Gram-Negative Infections Market Value, By Segment2, 2018 – 2028
TABLE  North America Hospital-Treated Gram-Negative Infections Market Value, By Country, 2018 – 2028
TABLE  Europe Hospital-Treated Gram-Negative Infections Market Value, By Segment1, 2018 – 2028
TABLE  Europe Hospital-Treated Gram-Negative Infections Market Value, By Segment2, 2018 – 2028
TABLE  Europe Hospital-Treated Gram-Negative Infections Market Value, By Country, 2018 – 2028
TABLE  Asia Pacific Hospital-Treated Gram-Negative Infections Market Value, By Segment1, 2018 – 2028
TABLE  Asia Pacific Hospital-Treated Gram-Negative Infections Market Value, By Segment2, 2018 – 2028
TABLE  Asia Pacific Hospital-Treated Gram-Negative Infections Market Value, By Country, 2018 – 2028
TABLE  Latin America Hospital-Treated Gram-Negative Infections Market Value, By Segment1, 2018 – 2028
TABLE  Latin America Hospital-Treated Gram-Negative Infections Market Value, By Segment2, 2018 – 2028
TABLE  Latin America Hospital-Treated Gram-Negative Infections Market Value, By Country, 2018 – 2028
TABLE  MEA Hospital-Treated Gram-Negative Infections Market Value, By Segment1, 2018 – 2028
TABLE  MEA Hospital-Treated Gram-Negative Infections Market Value, By Segment2, 2018 – 2028
TABLE  MEA Hospital-Treated Gram-Negative Infections Market Value, By Country, 2018 – 2028
TABLE  Merck and Co., Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Pfizer Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  AstraZeneca plc: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Abbott Laboratories: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Lupin Limited: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Istituto Lusofarmaco D'Italia SpA: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  ADELCO: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Zhejiang yuntao biotechnology co., Ltd: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  GlaxoSmithKline plc: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Novartis International AG: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
 

List of Figures

FIG.  Global Hospital-Treated Gram-Negative Infections Market: Research Methodology
FIG.  Top-Down and Bottom Up Approach
FIG.  Global Hospital-Treated Gram-Negative Infections Market, By Segment1, 2019 (US$ Mn)
FIG.  Global Hospital-Treated Gram-Negative Infections Market, By Segment2, 2019 (US$ Mn)
FIG.  Global Hospital-Treated Gram-Negative Infections Market, By Geography, 2019 (US$ Mn)
FIG.  Global Hospital-Treated Gram-Negative Infections Market Value and Growth, 2018 – 2028, (US$ Mn) (Y-o-Y %)
FIG.  Attractive Investment Proposition
FIG.  Market Positioning of Key Hospital-Treated Gram-Negative Infections Providers, 2016
FIG.  Global Hospital-Treated Gram-Negative Infections Market Value Share, By Segment1, 2019 & 2028 (% Value)
FIG.  Global Acinetobacter Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Coli Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Cepacia Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Pseudomonas Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Serratia Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Enterobacter Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Others Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Hospital-Treated Gram-Negative Infections Market Value Share, By Segment2, 2019 & 2028 (% Value)
FIG.  Global Lab Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Market Value, 2018 – 2028, (US$ Mn)
FIG.  U.S. Hospital-Treated Gram-Negative Infections Market Value, 2018 – 2028, (US$ Mn)
FIG.  Canada Hospital-Treated Gram-Negative Infections Market Value, 2018 – 2028, (US$ Mn)
FIG.  UK Hospital-Treated Gram-Negative Infections Market Value, 2018 – 2028, (US$ Mn)
FIG.  Germany Hospital-Treated Gram-Negative Infections Market Value, 2018 – 2028, (US$ Mn)
FIG.  France Hospital-Treated Gram-Negative Infections Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Europe Hospital-Treated Gram-Negative Infections Market Value, 2018 – 2028, (US$ Mn)
FIG.  China Hospital-Treated Gram-Negative Infections Market Value, 2018 – 2028, (US$ Mn)
FIG.  Japan Hospital-Treated Gram-Negative Infections Market Value, 2018 – 2028, (US$ Mn)
FIG.  India Hospital-Treated Gram-Negative Infections Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Asia Pacific Hospital-Treated Gram-Negative Infections Market Value, 2018 – 2028, (US$ Mn)
FIG.  Mexico Hospital-Treated Gram-Negative Infections Market Value, 2018 – 2028, (US$ Mn)
FIG.  Brazil Hospital-Treated Gram-Negative Infections Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Latin America Hospital-Treated Gram-Negative Infections Market Value, 2018 – 2028, (US$ Mn)
FIG.  GCC Countries Hospital-Treated Gram-Negative Infections Market Value, 2018 – 2028, (US$ Mn)
FIG.  South Africa Hospital-Treated Gram-Negative Infections Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of MEA Hospital-Treated Gram-Negative Infections Market Value, 2018 – 2028, (US$ Mn)